Roche Diagnostics, Basel, Switzerland, says FDA has cleared the company’s Cobas Pro integrated laboratory solution, the company’s new clinical chemistry and immunochemistry serum work area solution designed to optimize laboratory operations. The new work area solution enables laboratories to run tests faster on less equipment, automate manual tasks, and deliver results more quickly.


Thomas Schinecker, Roche Diagnostics.

The Cobas Pro integrated solution allows for the performance of up to 2,200 tests per hour, with three modules working in parallel and synchronized to improve efficiency. The new laboratory plan requires 3.25 hours less operating time for a daily routine workload than the Cobas 6000 analyzer, while 93% of Roche immunoassays have reaction times of 18 minutes or less. Reducing the time required to deliver results to physicians and patients across a number of therapeutic areas, including blood screening, core lab/HIV testing, and pregnancy testing, is vital for clinical decisionmaking, Roche says.

“We are excited about the accelerated FDA clearance of the Cobas Pro integrated solution, our new generation of serum work area solutions inspired by our mission to help improve speed and reliability of treatment decisions for patients and their families,” says Thomas Schinecker, CEO of Roche Diagnostics. “Reliable, fast, and sustainable diagnostic solutions are vital for optimal clinical care delivery for patients and a key element in the evolution of general healthcare quality.”

For more information, visit Roche Diagnostics.